Combination immunotherapy with Herceptin and the HER2 vaccine E75 in low and intermediate HER2- expressing breast cancer patients to prevent recurrence

This is a randomized trial for after all neo or adjuvant therapy is complete for women are Her2 1+ or HER2 2+

Primary Sponsor:
Departmental

Prinicipal Investigator:
Anita McSwain, MD

Contact Phone:
(202) 741-3379

Are you interested in more information on this clinical trial?

First Name *
Last Name *
Email *
Street Address *
City *
State *
Zip Code *
Phone Number 
     
Verification Code *

Please type what you see (all uppercase):